您的当前位置: 首页 > 产品 > 产品详情 > HA601134

Anti-Dxd Mouse Monoclonal Antibody [PSH0-37]

小鼠单抗 | 货号: HA601134


规格:

价格:RMB   1500
现在订购,【现货】
相关产品:

暂无,点击查看热门产品

  • 概述

  • 产品描述 Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM, but the control IgG-ADC (Dxd is the payload) shows no inhibition on the four cell lines (with HER2 expression). DS-8201a (Dxd is the payload) displays significant suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines, with IC50 values of 26.8, 25.4, and 6.7 ng/mL, respectively, but with no such inhibition on MDA-MB-468. DXd is a part structure of DS-1062a which is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of a humanized anti-TROP2 monoclonal antibody, enzymatically cleavable peptide-linker, and DXd. DXd is an important part structure of DS-7300a, a novel B7-H3-targeting ADC, using DXd-ADC technology, which is composed of a humanized anti-B7-H3 mAb, an enzymatically cleavable tetra-peptide-based linker, and a potent TOP1 inhibitor, DXd.
  • 产品名称 Anti-Dxd Mouse Monoclonal Antibody [PSH0-37]
  • 种属反应性 Species independent
  • 验证应用 ELISA
  • 抗体类型 小鼠单抗
  • 免疫原 Dxd-OVA
  • 偶联 Non-conjugated
  • 性能

  • 形态 Liquid
  • 浓度 1 mg/ml
  • 存放说明 Store at +4℃ after thawing. Aliquot store at -20℃. Avoid repeated freeze / thaw cycles.
  • 存储缓冲液 PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
  • 亚型 IgG1
  • 纯化方式 Protein A affinity purified.
  • 其它名称
    • DXD antibody
  • 应用

    ELISA: 1:1,000

  • 背景文献

  • 1. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Preclinical Efficacy of DS-8201a, a Novel HER2-Targeting ADC[J]. Clinical Cancer Research, 2016, 22(20): 5097-5108.

    2. Okajima D, Yasuda S, Yokouchi Y, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd[J]. 2018.
  • Publishing research using Anti-Dxd Mouse Monoclonal Antibody? Please let us know so that we can cite the reference in this datasheet.

Choose your product,application and species below,then click "Submit".

On the next page you can complete and submit your review.

  • * Code No.
  • *Application
  • *Sample
  • Species Tested
  • Against
  • Choose text
  • Content

Leave us a review

Specific Protocols

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

Click here to view the general protocols